101 results about "Cardiac disorders" patented technology

The invention discloses a signal acquisition system of a self-adaptive film electrode patch for heart diseases, and relates to the technical field of medical instruments, the signal acquisition system comprises a flexible substrate, a nano electrode wire, an electrode patch and a circuit module; a bonding layer is arranged on the bottom surface of the flexible substrate, an anti-allergic medicine is distributed in the bonding layer, and the flexible substrate is used for being attached to the skin surface through the bonding layer; the plurality of nano electrode wires are distributed on the bonding layer of the flexible substrate, one ends of the plurality of nano electrode wires are respectively arranged at the detection points, the other ends of the plurality of electrode wires are connected with the circuit module, and the circuit module is used for outputting electric signals collected by the electrode paste; the electrode patch comprises a flexible conductive base layer and a contact layer, a printed circuit is arranged on one side of the flexible conductive base layer, the contact layer is attached to the printed circuit, the other side of the flexible conductive base layer is used for being bonded to a flexible substrate and located at a detection point, and the flexible conductive base layer is conducted with the nano electrode wire; the collection system is simple to operate, and solves the problems that an existing lead wire is easy to wind, the surgical field is affected, and skin allergy is caused by patch. The method has high use value and popularization value.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

The invention relates to the technical field of biological medicines, in particular to application of a monoclonal antibody in medicines for treating heart diseases related to Alzheimer's disease. According to the application disclosed by the invention, the application range of the lencanamazumab is expanded to prevention and treatment of AD-accompanied heart failure and pathological myocardial remodeling, and a new drug strategy is provided for treatment of patients with AD-associated heart failure or pathological myocardial remodeling.

Methods and kits for treating and / or preventing a cardiac disorder are disclosed. The methods can include administering an indole metabolite to a subject. The methods can also include administering a glycopeptide antibiotic to the subject.

The present invention provides novel 4-methylsulfone-substituted piperidine / urea compounds useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and / or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds, as well as methods for the treatment of DCM and other forms of heart disease, are described.

Disclosed herein are methods and compositions for the detection of biomarkers for cardiac diseases. Disclosed herein are sample collection devices comprising detection devices for heart failure. Disclosed herein are methods of detecting, monitoring, preventing, or treating heart failure.

The invention discloses a medicine for treating the heart of a human body, and particularly relates to the field of medicines, the medicine is prepared from the following components in percentage by mass: 13.8% of radix salviae miltiorrhizae, 4.1% of allium macrostemon, 8.3% of semen trichosanthis, 2% of polygala tenuifolia, 8.3% of radix ophiopogonis, 2% of sandalwood, 6.9% of pericarpium citri reticulatae viride, 13.8% of lily, 8.3% of semen boitae, 10.4% of poria cocos, 8.3% of oriental cherry powder and 13.8% of earthworm, and the sum of the mass percentages of the components is 100%. According to the medicine for treating the heart of the human body, traditional Chinese medicine decoction pieces such as salvia miltiorrhiza, allium macrostemon, snakegourd seeds, polygala tenuifolia, radix ophiopogonis, sandalwood, pericarpium citri reticulatae viride, lily, platycladi seeds, poria cocos, oriental cherry powder and lumbricus are crushed and proportioned according to corresponding formula proportions and processes, so that the medicine plays the maximum effects of all the decoction pieces, is easier to take and absorb, and can be taken for a long time after being taken. The traditional Chinese medicine composition has obvious treatment effects on cardiac insufficiency, dyspnea, weakness, fatigue, angina pectoris, palpitation, palpitation and other problems caused by heart problems of heart disease patients, and can effectively treat coronary heart disease, myocardial ischemia, arrhythmia and other heart diseases.

The present application relates to a kind of cardiac magnetic resonance longitudinal relaxation time measurement method, medium and equipment.The measurement method includes the following steps: S1 uses MOLLI sequence respectively before and after scanning contrast;Specifically, in the before and after scanning contrast, by setting different initial inversion time TI, setting 3 groups of LL experiment LL1, LL2, LL3 triggered by continuous ECG, enough relaxation curve sampling points are obtained after fusion;And data is collected at the end of diastole of cardiac cycle, and 1 image is obtained per heartbeat;S2 image processing.This measurement method can realize single-pixel high-resolution T1 mapping under the breath holding of selection data acquisition and multi-LL experiment data fusion, give consideration to high accuracy, high resolution and high efficiency, and have good compatibility and practicality, provide new scheme for early diagnosis of heart disease, lesion quantification and prognosis evaluation, have wide clinical application prospect.

The application belongs to the technical field of model prediction, and relates to an abnormality identification method applied to electrocardiograms and related equipment.The method comprises the following steps: performing a first vector conversion operation on historical electrocardiogram data according to an encoding model to obtain a historical time sequence embedding vector; constructing an initial text prototype and calculating an initial text embedding vector of the initial text prototype according to a contrast learning function and the historical time sequence embedding vector; constructing a model loss function according to the historical time sequence embedding vector and the initial text embedding vector; performing a model training operation on the text prototype according to the model loss function to obtain a target text prototype; receiving electrocardiogram data to be analyzed sent by a user terminal; performing a second vector conversion operation on the electrocardiogram data to be analyzed according to a loss encoding model to obtain a time sequence embedding vector to be analyzed; inputting the time sequence embedding vector to be analyzed into the target text prototype to perform an abnormality identification operation and obtaining an abnormality identification result.The application can greatly improve the prediction accuracy of heart diseases.

The disclosure relates to RNAi constructs, such as siRNA, for reducing expression of the TTR gene. Methods of using such RNAi constructs to treat or prevent cardiac disease, such as transthyretin-associated cardiomyopathy (ATTR-CM), are also described.

The invention provides a 3D culture method for promoting stem cells to be differentiated into cardiac lineage cells. According to the method, four-stage time sequence induction is adopted, wherein in the stage I, BMP4, Activin A and bFGF are used for efficiently inducing the cells into mesoderm in an insulin-free culture medium; in the stage II, DKK1 is used for inhibiting WNT signals to lock the heart pedigree, and VEGF165 is added in the early stage to start cardiac endothelial differentiation; in the stage III, metabolic support is provided for an insulin-containing culture medium, and bilineage maturation is deepened; in the IV stage, bFGF is added to support long-term survival and function maintenance of the cells, and the whole process is carried out in a 3D embryoid body. According to the invention, the cheap RPMI1640 basal culture medium is used for replacing an expensive commercial culture medium, the high-purity heart micro-tissue which can spontaneously beat and contains cardiac muscle and cardiac endothelial cells can be obtained within about 10 days, and an economical and efficient cell source is provided for heart disease research, drug screening and regenerative medicine.

Disclosed herein, in some aspects, are systems and methods for detecting, monitoring, and managing a cardiac health status for a subject using ECG data. In some embodiments, the system receives health parameter measurements from one or more devices that are then used by a cardiac health tool (CHT) to determine a cardiac health status. Exemplary health parameter measurements include electrocardiogram (ECG) data from an ECG device and / or weight (from a weight scale for example). As described herein, in some embodiments, determining the cardiac health status includes a) detecting a cardiac condition in the subject, b) predicting a risk of a subject developing a cardiac condition (“cardiac condition risk”), and / or c) temporal monitoring of a cardiac health status for a subject. In some embodiments, the cardiac health tool is configured to determine the efficacy of a treatment or therapy applied to reduce the severity and / or risk of a cardiac condition.

The present disclosure provides beating explanted donor hearts from swine, methods of making thereof, and methods of using thereof. The present disclosure further provides methods of treating a disease (e.g., a heart disease) in a human subject in need thereof comprising transplanting of a beating explanted donor heart from swine. The present disclosure also provides medical instruments suitable for transplanting a beating explanted donor heart from swine.

The present invention relates to methods of immunoassay for detecting a biomarker which is an MMP-cleaved fragment of collagen type-I and its use in detecting and / or monitoring diseases such as kidney disease and diseases of the cardiovascular system including the heart.

The invention provides an application and a method of GSH in promoting mature differentiation of hiPSC-CMs, and the method is characterized in that in the process of directionally differentiating the hiPSC-CMs into the hiPSC-CMs, an effective dose of GSH is added into a differential medium, and the optimal concentration is 20-100 [mu] M. According to the invention, through simple and economical exogenous supplement of GSH, maturation of hiPSC-CMs is systematically promoted from multiple dimensions, including enhancement of intracellular anti-oxidation defense capability; energy metabolism is promoted to be converted from glycolysis to oxidative phosphorylation; up-regulating expression of cardiac muscle cell specific structural protein and calcium ion channel related genes; mitochondrial biological generation and functions are promoted; and the cell morphological structure is induced to develop to a mature phenotype. The method is simple and convenient to operate and high in biocompatibility, the hiPSC-CMs with mature functions can be stably obtained, and a high-quality cell source is provided for application of the hiPSC-CMs in the fields of heart disease modeling, drug cardiotoxicity screening and the like.

The application discloses a heart disease detection system based on an electrocardiosignal, and the system comprises an acquisition module configured to acquire an electrocardiosignal to be detected, a preprocessing module configured to perform a preprocessing operation on the electrocardiosignal to be detected, extract a wave band vector, a beat vector and a window segment vector from the preprocessed signal, convert the wave band vector into a wave band input matrix, and convert the beat vector into a beat input matrix, and a detection module configured to input the preprocessed electrocardiosignal into a trained heart disease detection model and output a heart disease detection result. The application can improve the accuracy of heart disease detection.

This disclosure is in the field of cardiac diseases. For example, the disclosure provides a new platform comprising iPSC and cardiomyocytes carrying one or more gene mutations, and models to study the effect of those gene mutations on cardiomyocytes, and on drug toxicity. This platform is identified herein as PREDICT PLATFORM.

This invention belongs to the field of biomedical engineering and relates to the application of SnoRNA Gm26330 as a biomarker and therapeutic target for myocardial hypertrophy. This invention provides a biomarker for myocardial hypertrophy, snoRNA Gm26330, the nucleotide sequence of which is shown in SEQ ID No. 1. In vitro and in vivo experiments have shown that SnoRNA Gm26330 can inhibit myocardial hypertrophy and has a protective effect against myocardial damage caused by myocardial hypertrophy. SnoRNA Gm26330 has potential value in the preparation of drugs for the prevention and treatment of related heart diseases.

The present invention relates to the use of Apoptosis Signal-Regulating Kinase-1 (ASK-1) inhibitor compounds for the treatment of organ diseases and disorders, wherein the organ disease or disorder is selected from a liver, heart disease, kidney, pancreas, spleen, or skin disease or disorder.

The embodiment of the invention discloses a three-dimensional myocardial scar visualization system. According to one specific embodiment, the system comprises a data processing end configured to perform heart structure and scar segmentation on target heart magnetic resonance data to obtain a binary tag graph for the heart and the myocardium; constructing an individualized ventricular network and a scar three-dimensional surface model based on the binary label graph; generating an initial myocardial scar three-dimensional model; generating lead implantation track information; generating a myocardial scar three-dimensional model according to the lead implantation track information; and the model application end is configured to perform model rendering on a target application page according to the model parameters corresponding to the myocardial scar three-dimensional model sent by the data processing end so as to provide an interactive operation function and generate a clinical report. According to the embodiment, accurate and visual three-dimensional visual decision support can be provided for preoperative planning and intraoperative navigation of heart diseases, so that the accuracy of surgical planning and the clinical working efficiency are remarkably improved.

The present application belongs to the technical field of organic electrochemical transistors, and particularly relates to a fast-response fiber vertical organic electrochemical transistor and a preparation method thereof. The fast-response fiber vertical organic electrochemical transistor is prepared by winding a thin film source electrode on a curved surface of a fiber drain electrode to form a coaxial step configuration of the source-drain electrode structure, and then loading an organic semiconductor layer at the step to form a small-size vertical channel. The fiber organic electrochemical transistor has the characteristics of fast response speed and high transconductance value, and maintains stable performance in cycle switching, dynamic deformation and long-term immersion. Immunohistochemical analysis shows that the fiber organic electrochemical transistor has excellent biocompatibility. The fiber organic electrochemical transistor can realize real-time monitoring of the fast-changing electrocardio signal in the biological soft tissue, and is used for diagnosis and long-term management of heart diseases, thereby providing a powerful new tool for life science basic research and clinical diagnosis.

The invention provides an application of up-regulated human enoyl coenzyme A delta isomerase 2 (ECI2) in preparation of a medicine for protecting a cardiac function. It is found for the first time that up-regulation of ECI2 promotes degradation of crotonyl coenzyme A by consuming a crotonyl donor (crotonyl coenzyme A) and effectively inhibits crotonyl modification, so that the heart function and myocardial hypertrophy can be effectively improved, and then the heart function protection effect on pressure overload heart diseases and heart failure is achieved. The above findings indicate a huge potential of upregulating ECI2 in the prevention and / or treatment of pressure overload heart diseases and heart failure.

An information processing technology capable of increasing prediction accuracy of causing cardiac diseases, performing appropriate therapy and increasing efficiency of drug development is constructed by utilizing “in-silico cardiac disease database.” An electrocardiogram and the like obtained from “in-silico cardiac disease database” which is the database storing a simulation result of a cardiac model of virtual disease where various factor related to cardiac disease are changed are inputted to a classifier for performing an automatic diagnosis of the cardiac disease, and an influencing factor associated with the cardiac disease is identified as a biomarker by comparing distributions of a variation amount of a factor between a positive group and a negative group. In addition, precise diagnosis of an individual is easily performed by identifying the cardiac model having the electrocardiogram and the like appropriate to the actual electrocardiogram and the like of the individual in the in-silico cardiac disease database. Furthermore, the process of drug development is efficiently performed by extracting a group having a predetermined feature from the in-silico cardiac disease database and simply evaluating an effect of an administration of a medical agent.

The invention provides modified apelin polypeptides having increased stability, circulating half-life, and / or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

This invention discloses an intelligent recognition method and system for cardiac CT images based on convolutional neural networks, belonging to the field of medical image intelligent recognition technology. The method includes the following steps: constructing a fusion model of an improved ResNet-12 and a residual hybrid attention module; extracting deep local features from cardiac CT images through the improved ResNet-12 and enhancing the channel and spatial features of lesion areas through the residual hybrid attention module, thereby achieving accurate recognition of multiple types of cardiac diseases; preprocessing the input cardiac CT images, including CT value normalization, size unification, and data augmentation, outputting standardized feature data; and embedding the residual hybrid attention module after the residual module of the improved ResNet-12. This invention ensures generalization ability in scenarios with limited samples in primary healthcare institutions, ultimately improving the efficiency and accuracy of cardiac disease diagnosis.

The invention relates to the technical field of storage shelves, in particular to a wearable electrocardiogram monitoring device and a data real-time acquisition system and method.The wearable electrocardiogram monitoring device comprises a base, a host and a connecting electrode and further comprises a medicine box assembly, the medicine box assembly comprises a connecting frame, a containing box, an elastic piece, a clamping block, a pushing plate, a connecting component and a moving component, and the connecting frame is fixedly connected with the host; the placing box is connected with the connecting frame through the connecting component, the elastic piece is fixedly connected with the placing box, the clamping block is fixedly connected with the elastic piece, the pushing plate is connected with the connecting frame through the moving component, the connecting component is arranged on the connecting frame and connected with the placing box, the moving component is arranged on the connecting frame and connected with the pushing plate, and the connecting frame is provided with a clamping groove and a containing groove. According to the device, medicine is stored through the arranged containing box, a user can take the first-aid medicine placed in the containing box conveniently, then a patient suffering from heart diseases can be helped to cope with an emergency situation when carrying the device, and life safety is guaranteed.

The utility model discloses a kind of radiofrequency ablation needle assemblies and ablation systems containing multifunctional divining rod type coaxial sheath, which ablation assembly includes multipurpose double-channel divining rod type insulating coaxial sheath and ablation needle, divining rod type insulating coaxial sheath is detachably connected with handle, and position adjusting member on handle realizes self-adaptive adjustment of ablation needle working end length, divining rod type insulating coaxial sheath synchronously realizes ablation, biopsy, pericardial effusion drainage, cardiac conduction bundle position marking, myocardial drug injection, ICD implantation and cardiac ECG monitoring and other surgical auxiliary diagnosis and treatment, to ensure that integrated intramyocardial intervention diagnosis and treatment are safely and effectively completed, the ablation needle assembly containing multipurpose divining rod type sheath in the utility model breaks through the bottleneck of low efficiency, complicated operation and many complications of existing radiofrequency ablation technology, and provides an innovative solution for comprehensive interventional treatment of heart disease and various tumor diseases.

Nucleic acid molecules comprising truncated forms of the human cytomegalovirus (CMV) promoter are operably linked to a transgene of interest, including those encoding eNOS protein are taught. Vectors comprising these nucleic acid molecules and host cells transformed by these vectors and methods of producing cellular compositions are used for the treatment of a variety of pulmonary and cardiac diseases. There is provided a truncated human cytomegalovirus (CMV) enhancer element comprising SEQ ID NO: 1 or a functional derivative thereof. A truncated human cytomegalovirus (CMV) promoter comprising the truncated CMV enhancer element is taught. A polynucleotide expression cassette comprising the truncated CMV promoter and a transcribable polynucleotide operably linked to the truncated CMV promoter polynucleotide construct, a host cell comprising the polynucleotide expression cassette, and use of the host cell treat renal, vascular, pulmonary, or cardiac disease in the patient are taught.

The application provides an electrode for cardiac tissue pulse field ablation, a preparation method and a use method, the electrode has a multi-stage partition structure, each partition contains at least a pair of independently activated electrode pairs, the cathode and the anode of the electrode pair are arranged alternately, the distance between the anode and the cathode in the electrode pair gradually decreases from outside to inside, by activating different electrode pairs, the direction and intensity of the electric field are adjusted to adapt to the ablation requirements of different depths and ranges of cardiac tissue. The application also provides a preparation method and a use method of the electrode. The application can accurately control the distribution and intensity of the pulse field, realize deep tissue penetration at a lower voltage, and thus improve the effectiveness and safety of cardiac disease treatment.